ArticlePloS one2025
Validation and potential refinement of the Malaysia Medication Adherence Assessment Tool (MyMAAT) among patients with non-dialysis chronic kidney disease.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication adherence is essential for managing chronic kidney disease (CKD) and preventing its progression. In Malaysia, adherence is commonly assessed using the 12-item Likert scale Malaysia Medication Adherence Assessment Tool (MyMAAT-12), but it has not been validated for CKD patients. Thus, this study aimed to validate and explore its potential for item reduction among non-dialysis CKD patients. METHODS AND
findingsA cross-sectional, multi-center study was conducted across eight health facilities in Pahang state from December 2023 to August 2024. Non-dialysis CKD patients aged 18 years and above, with or without diabetes, attending outpatient clinics, were given the 12-item self-administered MyMAAT-12 and items from the Beliefs about Medicines Questionnaire (BMQ). Patient demographics, HbA1c levels, and serum phosphate changes within three months preceding MyMAAT-12 completion were collected. The dimensionality of the scale was explored through exploratory factor analysis (EFA), and its reliability and criterion validity were evaluated to ensure robust measurement properties. A simulation test was conducted to explore the feasibility of reducing MyMAAT-12 to a shorter version. A total of 246 respondents participated, predominantly female (54.5%) and Malay (91.5%), with a mean age of 59.5 ± 12.5 years and an average CKD duration of 5.0 ± 5.4 years. The average medication adherence score was poor to moderate (<54/60). MyMAAT-12 demonstrated excellent internal consistency (Cronbach's alpha = 0.90) and significant association with BMQ categories (χ²(2) = 16.8, p < 0.01). EFA identified a two-factor structure. MyMAAT-12 adherence categorization was significantly associated with HbA1c% (<8% vs. ≥ 8%) (χ2(2) = 4.7, p = 0.03) and phosphate level changes (χ2(2) = 5.48, p = 0.02). Results indicated that reducing MyMAAT-12 to a 7-item scale was feasible, while maintaining strong psychometric properties (Cronbach's alpha = 0.87) and a significant association with HbA1c% (ρ = -0.22, p = 0.01).
conclusionMyMAAT-12 demonstrated strong reliability and validity, making it a valuable tool for clinicians to accurately assess medication adherence in non-dialysis CKD patients. The shortened MyMAAT-7 offers a streamlined alternative with strong psychometric properties, enhancing clinical practicality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.